Compounds of formula I: in free or salt or solvate form, where R
1
, R
2
, R
3
and R
20
have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described. These compounds are useful for the treatment of inflammatory or obstructive airways diseases such as pulmonary hypertension, pulmonary fibrosis, liver fibrosis, cancer, muscle diseases such as muscle atrophies and muscle dystrophies, and systemic skeletal disorders such as osteoporosis.
Ruthenium-Catalyzed Divergent Acceptorless Dehydrogenative Coupling of 1,3-Diols with Arylhydrazines: Synthesis of Pyrazoles and 2-Pyrazolines
作者:Yanling Zheng、Yang Long、Huihua Gong、Jiaqi Xu、Chunchun Zhang、Haiyan Fu、Xueli Zheng、Hua Chen、Ruixiang Li
DOI:10.1021/acs.orglett.2c01497
日期:2022.6.3
1,3-diols with arylhydrazines via acceptorless dehydrogenativecoupling reactions to selectively synthesize pyrazoles and 2-pyrazolines were reported, which were based on Ru3(CO)12/NHC-phosphine-phosphine catalytic systems. The reactions featured low catalyst loading, high selectivity, wide substrate scope, and good yields, with only water and hydrogen gas (H2) as the byproducts.